Undisclosed U.S.-based biotech company

Metsera is a clinical-stage biopharmaceutical company focused on developing the next generation of medicines for obesity and cardiometabolic diseases. Founded by Arch Venture Partners and Population Health Partners, the company emerged from stealth in 2024 with a diverse portfolio of oral and injectable incretin, non-incretin, and combination therapy candidates. Its lead programs include MET-097i, an ultra-long-acting GLP-1 receptor agonist designed for weekly or monthly dosing, and MET-233i, a monthly amylin analog combination. In late 2025, Metsera was acquired by Pfizer in a deal valued at up to $10 billion, significantly strengthening Pfizer's position in the high-growth obesity market. The company's approach emphasizes best-in-class efficacy, tolerability, and dosing convenience to address long-term patient adherence.